Drug Profile
Research programme: haemostatic agent - Entegrion
Alternative Names: StasixLatest Information Update: 19 Sep 2023
Price :
$50
*
At a glance
- Originator Entegrion
- Class Blood products and substitutes
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haemorrhage
Most Recent Events
- 19 Sep 2023 Discontinued - Preclinical for Haemorrhage in USA (IV) (Entegrion website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Haemorrhage in USA (IV, Infusion)
- 11 Aug 2016 Preclinical trials in Haemorrhage in USA (IV)